RESHAPING THE FUTURE OF ATRIAL FIBRILLATION EP MANAGEMENT
This session has been co-developed by the Canadian Cardiovascular Society and sanofi-aventis Canada Inc.

Chair: Charles Kerr

Target Audience:
Clinical cardiologists
Electrophysiologists

Program

1. Welcome & Introduction

2. Atrial Fibrillation - a marker of cardiovascular risk
Malcolm Arnold

3. The rationale for outcome studies in atrial fibrillation
Paul Dorian

4. Challenges of atrial fibrillation treatment in heart failure patients (AF-CHF study)
Denis Roy

5. ATHENA - a landmark study in atrial fibrillation and clinical implications
Stuart Connolly

6. Conclusion

SATELLITE SYMPOSIUM
This session has been co-developed by the Canadian Cardiovascular Society and Boehringer Ingelheim Canada Ltd.

Management of High-risk Patients: Recent Advances and Clinical Implications

Please note that dinner will be served during this satellite symposium.

Program

SATELLITE SYMPOSIUM
This session has been co-developed by the Canadian Cardiovascular Society and AstraZeneca Canada Inc.

The CV Show: Expert Insights into Atherosclerotic Vulnerability in the Vulnerable Patient

Breakfast will be served at 06:30.

Chair: Jacques Genest

Screening for early-stage asymptomatic cancers (e.g. breast or colon cancer) to prevent late-stage malignancies has been widely accepted. However, although atherosclerotic cardiovascular disease (e.g. heart attack and stroke) accounts for more death and disability than all cancers combined, there are no national screening guidelines for asymptomatic (sub-clinical) atherosclerosis, and there is no government or healthcare-sponsored reimbursement for atherosclerosis screening.
The objective of this discussion is to review, discuss and recognize the evidence and new discoveries in the field of atherosclerosis, which have led to the concept of “vulnerable plaque to vulnerable patient.”

This landmark evidence, along with new diagnostic and therapeutic options, has set the stage for the next step: translation of this knowledge into a new practice of preventive cardiology.

Agenda

The Biological Basis of Atherosclerotic Vulnerability

How Early to Treat? Maximizing the Benefits of Statin Therapy

Surrogate Endpoints as a Compliment to Clinical Outcomes OR Non Invasive Imaging

Techniques of Atherosclerosis and Clinical Practice: What Do They Tell Us?

Should Atherosclerosis Imaging Redefine the At-risk Patient?

SATELLITE SYMPOSIUM
This session has been co-developed by the Canadian Cardiovascular Society and Abbott Vascular, AstraZeneca Canada Inc. and sanofi-aventis

Expert Opinions - Advances in Cardiology

Buffet dinner will be served during this program.

The 6th annual Expert Opinions-Advances in Cardiology focuses once again on the leading issues of the day in the management of the cardiac patient. Clinicians attending this program will be exposed to world-class faculty offering their perspective on what truly represents the advances in cardiology in 2008.

The topics this year include:

• Atherosclerotic Imaging - How can we effectively utilize these biomarkers to determine CV outcomes?
• Anticoagulation Therapy - As the body of evidence continues to grow, how will clinicians’ choices be affected in the ACS setting?
• Drug-eluting stent (DES) - Will the next generation of stents provide better outcomes in patients with CAD?
  
  

Participants attending this high-level educational program will gain a better understanding of strategies to address hypertension, dyslipidemia, and diabetes, three common yet challenging risk factors for the patient with cardiovascular and metabolic disease. 

This program will highlight:

• New treatment options and updated clinical practice guidelines for the management of diabetes
• The value of comprehensive lipid management and treating patients to both LDL-C & TC: HDL ratio Guidelines targets, and
• Emerging evidence and treatment options for the management of hypertension and cardiovascular disease in patients with renal risk factors

Please join our esteemed panel for an evening that will shed new light on an emerging health concern.

SATELLITE SYMPOSIUM
This session has been co-developed by the Canadian Cardiovascular Society and Eli Lilly Canada Inc.

Improving Outcomes with Antiplatelet Therapy: Practical Applications from New Research

Chair: Shamir Mehta

Through expert presentations and an interactive panel discussion, participants will be better able to:

• Discuss the current updated guidelines in treating ACS in patients
• Assess the efficacy and safety of current antiplatelet therapy for patient care
• Evaluate the latest clinical trial data for emerging antiplatelet therapies
• Describe the implications of various therapeutic options for patient care

Controversies in Antiplatelet Therapy
Shamir Mehta

Limitations of Current Antiplatelet Therapy in ACS and PCI
John Eikelboom

Recent Clinical Trial Data
Integrating Recent Data with Clinical Practice: A Canadian Perspective
Shaun Goodman

Optimal Treatment of STEMI in 2008
Mouhieddin Traboulsi

Emerging Antiplatelet Therapies and the Latest Clinical Trials
Pierre Théroux

SATELLITE SYMPOSIUM
This session has been co-developed by the Canadian Cardiovascular Society and Pfizer Canada Inc.

Straight From the Heart: Smoking Cessation Meets CV Risk Management

Objective

In this interactive and informative talk show, hosts Richard Ward and Jane Brownrigg will engage the audience and an expert panel on topics related to smoking cessation and cardiovascular (CV) risk factors management. Members of the audience will be able to ask questions of the experts and participate via an interactive audience response system using touchpad technology.

Participants in this program will be able to:

• Explain the relative impacts/contributions of various CV risk factors (i.e., hypertension, dyslipidemia, metabolic, smoking, obesity)
• Describe the top 3 challenges currently facing Canadian clinicians in the management of CV disease
• Describe the fundamental mechanisms that impel and maintain smoking behaviour, understanding that smoking is an addiction
• Utilize lifestyle, counselling and pharmacotherapy options to help patients quit smoking

Target Audience

Specialist physicians in cardiology, endocrinology, internal medicine, cardiovascular surgery and rehabilitation. This symposium will be very valuable for primary care physicians, trainees, and cardiac nurses and health educators.

Program

Reality check – what is the current situation in Canada in the management of CV risk and cardiac patients?

Identification of the top 3 Clinical Challenges in Cardiac Patients

Description of Smoking Cessation Strategies

Review of Foundations of Nicotine Addiction

Integration of Smoking Cessation Strategies into Overall CV Risk Management Paradigm

SATELLITE SYMPOSIUM
This session has been co-developed by the Canadian Cardiovascular Society and Servier Canada

Heart Rate Reduction and the Management of Cardiovascular Disease

Innovation in Cardiovascular Medicine
Jean-Claude Tardif

Heart Rate - A Neglected Risk Factor in Clinical Practice
Paul Dorian

Targeting Heart Rate: The BEAUTIfUL Study (Rationale, design and study population)
Jonathan Howlett

BEAUTIfUL Study - Main Results
Jean-Claude Tardif

Heart Rate Management in CAD: Weigh the Evidence, Consider the Options
David Fitchett

Concluding Remarks
Eva Lonn

SATELLITE SYMPOSIUM
This session has been co-developed by the Canadian Cardiovascular Society and the Canadian Cardiovascular Research Network.

CV Quest 2008: Progress and Promise

Promoting Cardiovascular Leaders Through Innovation
Tirone David

Building a Secure Research Community for Tomorrow
Peter Liu

New Drug Discovery or Closing the Care Gap: Where Should Our Money be Spent?

What Will the Future of Educational Models Look Like in 2025?

The Academia-Industry Interface: Is Balance and Transparency Attainable?
Spencer B. King
Atlanta, Georgia

SATELLITE SYMPOSIUM
This session has been co-developed by the Canadian Cardiovascular Society and Novartis Pharmaceuticals Canada Inc.

Multi-faceted approach to vascular risks: where are we headed?

1. Prioritizing Risk Reduction in Diabetes: BP Control vs Glycemic Control Debate Format
2. Unmet Needs in Heart Failure: Where are we Headed?
3. Optimizing DRI Use in Contemporary Practice
4. Case Based Illustrations- Round Table Discussion
   Jean Rouleau
   
   
   

SATELLITE SYMPOSIUM
This session has been co-developed by the Canadian Cardiovascular Society and Merck Frosst / Schering Pharmaceuticals, sanofi-aventis / Bristol-Myers Squibb Canada and sanofi-aventis Canada

Expert Opinions: Current Issues in Cardiology

Breakfast will be served at 06:30.

Chair: Jean Rouleau

The 5th annual Current Issues in Cardiology satellite symposium will expose Canadian clinicians to issues that go beyond clinical practice.  This symposium will highlight translational research and provide a unique “bench-to-bedside” perspective on some of the most remarkable research that is taking place in Canada and abroad in cardiology and related fields.  

Scientists are increasingly aware that this bench-to-bedside approach to translational research is really a two-way street. Basic scientists provide clinicians with new tools for use in patients and for assessment of their impact, and clinical researchers make novel observations about the nature and progression of disease that often stimulate basic investigations.  This satellite symposium will provide a forum in which leading Canadian and international researchers and clinicians will be able to expand upon some of the groundbreaking research that will influence the next generation of cardiac care.

Translational Feature Lecture - Is there a Genetic Link between Breast Cancer and Heart Disease?

Anti-Platelet Therapy - What are the Recent Advances that will Improve Outcomes for ACS Patients?

Oncology - The cardiotoxicity of older drugs is a growing concern for cardiologists.  What does recent research show us about the newest generation of oncology drugs?

Dyslipidemia - Will an understanding of the reciprocal relationship between cholesterol absorption and synthesis allow for the development of more effective interventions for dyslipdemic patients?